PROVEN, DEPLOYED AND SCALING

Ultromics’ EchoGo® suite of AI tools applies advanced deep learning to transform standard heart scans into precision diagnostics. Its AI is trained on one of the largest real-world echocardiogram datasets in the world, and analyses scans pixel by pixel, detecting hidden markers of heart disease to support earlier detection.

Commercially cleared and Medicare-reimbursed for heart failure, and built on more than a decade of patient data from leading partners like the University of Oxford and Mayo Clinic, EchoGo® delivers results in under 20 minutes with clinically proven accuracy.

These tools give frontline clinicians the insight they need to act sooner, guide the right treatment, and ultimately improve patient outcomes.

GLOBAL ROLLOUT

EchoGo® Heart Failure and EchoGo® Amyloidosis are world-first, AI-powered diagnostic support tools for echocardiography, and already FDA-cleared and deployed across multiple US hospital systems. The company has reimbursement in place from government and commercial payers.

In total, Ultromics has achieved four FDA clearances, and two Breakthrough Device designations. Its products have been validated across 25 peer-reviewed studies.

As the global burden of heart disease continues to rise, tools such as those in the EchoGo® suite are becoming critical to delivering faster, smarter, more equitable cardiac care – helping to close one of medicine’s most dangerous diagnostic gaps.

OSE has supported Ultromics since its earliest stages – helping it grow from Oxford lab to clinical deployment across the US.

With a world-class team, breakthrough technology, and clear commercial momentum, Ultromics is now working to expand its reach across more forms of heart disease – and bring precision cardiac diagnostics to patients around the world.

This is what OSE was built to do: back science with purpose, and build companies that save lives.